Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p14
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 14/16)
Character Range: 155120–158115

or less of cresols and xylenols and other homologues of phenol.
PHENYLEPHRINE except:
 (a) when included in Schedule 4; or
 (b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or
 (c) in topical eye or nasal preparations containing 1% or less of phenylephrine.
PHOLCODINE:
 (a) in liquid preparations containing 0.5% or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or
 (b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.
PIPERAZINE for human therapeutic use.
PODOPHYLLOTOXIN in preparations containing 0.5% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10% or less of podophyllin for human use for the treatment of warts other than anogenital warts.
POTASSIUM CHLORATE for therapeutic use except in preparations containing 10% or less of potassium chlorate.
PRILOCAINE in preparations for dermal use containing 10% or less of total local anaesthetic substances.
PROCYCLIDINE in preparations containing 5% or less of procyclidine for dermal use.
PROMETHAZINE in oral preparations:
 (a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or
 (b) when combined with one or more other therapeutically active substances when:

          (i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

          (ii) in a day‑night pack containing promethazine in the bed‑time dose where the day and night doses are in the same immediate container or immediate wrapper;
 except in preparations for the treatment of children under 2 years of age.
PROPAMIDINE for ophthalmic use.
PYRANTEL for human therapeutic use.
PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10% of such substances.
PYRITHIONE ZINC for human therapeutic use, except in preparations for the treatment of the scalp containing 2% or less of pyrithione zinc when compliant with the requirements of the required advisory statements for medicine labels.
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 7 days' supply.
RANITIDINE in preparations supplied in the manufacturer's original pack containing not more than 14 days' supply except:
 (a) in divided preparations for oral use